Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 Study of Telisotuzumab Adizutecan + Osimertinib as First-Line Therapy in EGFR-Mutated Non-Squamous NSCLC
2024-518586-10-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised trial of telisotuzumab adizutecan in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Phase 2: Objective response (OR) and Phase 3: Progression-free survival (PFS). Planned start Aug 2025; status: authorised.
02
Drugs
telisotuzumab adizutecan
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2024-518586-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518586-10-00.